These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12649110)

  • 1. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.
    Dumontet C; Jaubert J; Sebban C; Bouafia F; Ardiet C; Tranchand B; Berger E; Lucas C; Guyotat D; Coiffier B
    Ann Oncol; 2003 Apr; 14(4):615-22. PubMed ID: 12649110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
    Marinelli A; Lamberti G; Cerbone L; Cordua N; Buonerba C; Peluso G; Di Lorenzo G; De Placido S
    Medicine (Baltimore); 2018 Jul; 97(27):e11254. PubMed ID: 29979390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.
    Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T
    Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
    Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
    Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients.
    Egerer G; Lehnert T; Max R; Naeher H; Keilholz U; Ho AD
    Int J Clin Oncol; 2001 Feb; 6(1):25-8. PubMed ID: 11706523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 8. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R; Lucas C; Solere P; Cour V; Vignoud J
    Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
    Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
    BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
    Boiardi A; Silvani A; Ciusani E; Watson A; Margison G; Berger E; Lucas C; Giroux B
    J Neurooncol; 2001 Apr; 52(2):149-56. PubMed ID: 11508814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
    Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
    Pujol JL; Monnier A; Berille J; Cerrina ML; Douillard JY; Rivière A; Grandgirard A; Gouva S; Bizzari JP; Le Chevalier T
    Br J Cancer; 1994 Jun; 69(6):1136-40. PubMed ID: 8198982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.
    Lasset C; Merrouche Y; Negrier S; Rebattu P; Berille J; Bizzari JP; Chauvin F; Philip T
    Cancer Chemother Pharmacol; 1993; 32(4):329-31. PubMed ID: 8324878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.